Abiraterone acetate for prostate cancer: a new era of hormonal therapies

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2011,（5）
• 页码范围: 663-664
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.92

摘要

Therapies targeting the androgen receptor (AR) axis have constituted the Holy Grail in the management of advanced prostate cancer for seven decades.1 These hormonal therapies have traditionally taken two main forms: those that suppress gonadal androgen synthesis (e.g.,the gonadotropin releasing hormone agonists/antagonists,such as leuprolide),and those that inhibit the AR directly (e.g.,the anti-androgens,such asbicalutamide).However,although the vast majority of patients with prostate cancer initially respond favorably to androgen-ablative therapies (manifested by tumor regressions and symptomatic improvements),all patients will eventually develop further disease progression after a median of 18-24 months.This transformed disease state,known as castration-resistant prostate cancer (CRPC),is invariably fatal.